feedback

Course Director

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP

Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Faculty

Shaji Kumar
Shaji Kumar, MD

Mayo Clinic
Rochester, Minnesota

Robert Z. Orlowski
Robert Z. Orlowski, MD, PhD

The University of Texas
MD Anderson Cancer Center
Houston, Texas

Nina Shah
Nina Shah, MD

University of California San Francisco
San Francisco, California

Accredited by

Penn State College of Medicine

View Activity Materials

Activity Description and Educational Objectives

In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in daily practice and clearly shows how novel antibodies, immunotherapy, and other innovative strategies have shaped a new model for myeloma care.

Upon completion of this activity, participants should be better able to:
  • Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting
  • Integrate novel therapeutics into the management of newly diagnosed myeloma, including for patients with smoldering disease or those with symptomatic disease regardless of transplant eligibility
  • Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease
  • Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 17, 2020 - July 16, 2021
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty
Shaji Kumar, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Cellectar Biosciences, Inc.; GeneCentrix, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Molecular Partners; Oncopeptides AB; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb; CARsgen Therapeutics; Celgene Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Kite Pharma, Inc.; MedImmune; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals U.S.A., Inc.; and TeneoBio.

Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Director, Myeloma Section, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; Celgene Corporation; EcoR1 Capital LLC; Forma Therapeutics; Genzyme; GlaxoSmithKline Biologicals; Ionis Pharmaceuticals, Inc.; Janssen Biotech, Inc.; Juno Therapeutics, Inc.; Kite Pharma; Legend Biotech; Molecular Partners; Regeneron Pharmaceuticals, Inc.; Sanofi; Servier Laboratories; STATinMED, Research; and Takeda Pharmaceuticals U.S.A., Inc.
Grant/Research Support from BioTheryX, Inc.; CARsgen Therapeutics; Celgene Corporation; Exelixis, Inc.; Janssen Biotech, Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Other Financial or Material Support Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not directly bear on the current activity.

Nina Shah, MD
Associate Professor
Division of Hematology Oncology
University of California San Francisco
San Francisco, California

Nina Shah, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; Bristol Myers Squibb; CareDx; Genentech, Inc.; Indapta Therapeutics, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Kite Pharma; and Sanofi.
Grant/Research Support from Bristol Myers Squibb/Celgene Corporation; bluebird bio, Inc.; Janssen Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; and TeneoBio, Inc.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6633-21-T.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC Credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Providership

This CME/MOC activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi US.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/MOC Activity

PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.